Cancel

Hitting the Target in HER2-Positive Metastatic Colorectal Cancer

STATEMENT OF NEED An estimated 153,020 new cases of colorectal cancer (CRC) are diagnosed annually, and 52,550 people die of the disease (Siegel et al, 2023). Approximately 22% of patients present with metastatic disease, which is associated with a dismal 5-year survival rate of 15% (SEER, 2022). Targeting biomarkers is a key strategy for expanding therapeutic options and improving outcomes in metastatic CRC. Human epidermal growth factor receptor 2 (HER2) amplification status and treatment...
i3 Health

Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma

STATEMENT OF NEED An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, inclu...
i3 Health

Leveraging the Growing Arsenal of Adjuvant Therapies for Early-Stage NSCLC

In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non"small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now! STATEMENT OF NEED Lung cancer is the second most commonly diagnosed cancer and the leading cause of death for men and women worldwide. In the Unite...
i3 Health

Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer: Case Explorations and Answers to FAQs

STATEMENT OF NEED Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack ...
i3 Health

Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma

STATEMENT OF NEED Sarcomas, which represent 1% to 2% of adult cancers, are a rare, heterogeneous group of neoplasms originating in the connective tissue. Soft tissue sarcomas, which begin in the muscle, tendons, fat, lymph, blood vessels, and nerves, encompass more than 80 histological subtypes. Approximately 25% of patients develop metastatic disease after curative-intent surgery, and for these patients, treatment options are limited and prognosis is very poor. In recent decades, the ident...
i3 Health

Putting the Freeze on Cold Agglutinin Disease

STATEMENT OF NEED Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia (AIHA) in which antibodies cause hemolysis at cold temperatures, generally between 37º to 39º Fahrenheit. Approximately 1 in a million people are affected by CAD annually, with onset usually occurring between the ages of 40 and 80 years. Individuals commonly experience fatigue, dizziness, palpitations, and shortness of breath caused by the anemia; jaundice caused by degradation of hemoglobin i...
i3 Health

Managing Immune Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes: The Nurse’s View

STATEMENT OF NEED Immune checkpoint inhibitors, which alter immune regulatory pathways and promote cell-mediated destruction of tumor cells, have revolutionized the treatment of cancer in recent years, with numerous therapeutic agents approved and several targets under investigation (Chennamadhavuni et al, 2022). However, up to 90% of patients receiving immune checkpoint inhibitors experience immune-related adverse events, which can affect a wide variety of organ systems and can occur at any ...
i3 Health

New Guidance to Diagnose and Treat Tumor-induced Osteomalacia (TIO)

This 30-minute CME-accredited program, hosted by Aliya Khan, MD, Clinical Professor of Medicine at McMaster University, highlights the best practices to diagnose and treat tumor induced osteomalacia (TIO) based on the recently published global guidance document in the Journal of Internal Medicine. This activity has been designed to meet the educational needs of physicians specializing in neurology, orthopedics, internal medicine/general practice, rheumatology, endocrinology, pain management...
CheckRare

Current Standards and New Directions in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura

STATEMENT OF NEED Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening thrombotic microangiopathy with a rapid onset and progression and a mortality rate of 10% to 20% with prompt treatment. Onset of aTTP is characterized by severe thrombocytopenia, microangiopathic hemolytic anemia, and a constellation of associated symptoms including hemorrhage, neurologic and renal manifestations, cardiac abnormalities, and mesenteric ischemia (Joly et al, 2017). Survivors of f...
i3 Health

Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes

STATEMENT OF NEED Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ...
i3 Health

Exploring Novel Treatments for Rett Syndrome

STATEMENT OF NEED Rett syndrome is a rare, debilitating neurodevelopmental disorder almost always associated with a spontaneous mutation in the methyl-CpG-binding protein 2 (MECP2) gene on the X-chromosome. Affected individuals experience loss of purposeful hand skills, abnormalities in gait, loss of spoken language, and stereotypic hand movements, with more severe manifestations including seizures, autistic features, autonomic nervous system dysfunction, breathing abnormalities, sleep dist...
i3 Health

Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy

STATEMENT OF NEED Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to dose reductions or discontinuation of treatment. In one study, among 105 patients receiving paclitaxel for breast cancer, 36.2% needed dose reductions due to CIPN (Timmins et al, 2021). Whereas in some patients the symptoms improve with time, in others, there is progression with permanent nerve damage (Zajączkowska et al, 2019). At present, the...
i3 Health

Combining Locoregional and Systemic Therapy for Challenging HCC Cases

Target Audience This educational activity is intended for interventional oncologyists physicians, nurses, and other members of the health care team who care for patients with hepatocellular carcinoma (HCC) Program Overview This activity focuses on challenges in the management of HCC using the latest clinical data supporting locoregional therapy, and on strategies for greater collaboration amongst the multidisciplinary teams in community vs academic settings. Learning Objectives Upon c...
Society of Interventional Oncology and The France Foundation.

Warm Autoimmune Hemolytic Anemia (wAIHA)

Target Audience This activity has been designed to meet the educational needs of physicians specializing in hematology and hematology-oncology. Other members of the care team may also participate. Program Overview Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis. Current recommendations for managing ...
American Academy of CME, Inc. and and CheckRare CE.

Innovations and New Practices in Internal Medicine 2024 -LIVE STREAMING

The State of the Art in Internal Medicine This program, which is among the highest-rated Harvard Medical School CME courses, provides a comprehensive update of the most important changes now impacting Internal Medicine and guidance on how to incorporate these changes into your clinical practice to improve patient outcomes.. Practical, Fast-Paced, Online Education This live streaming educational experience is fast paced, relevant to the current healthcare environment, and draws upon real...
Harvard Medical School

WEBINAR BUNDLE: Veterinary Pharmacy Conference 2021 - On Demand

Earn up to 7 hours of continuing education focused on community veterinary pharmacy when you purchase the Veterinary Pharmacy Conference 2021 - On Demand. The ACVP Veterinary Pharmacy Virtual Conference is the only national conference designed exclusively for community veterinary pharmacies, ideal for new and established veterinary pharmacy practices. This conference is designed for pharmacists and pharmacy technicians and presents the latest clinical and practical topics. Session 1 -...
American College of Veterinary Pharmacists

WEBINAR: Metronomic Chemotherapy: Hope vs. Hype

Metronomic chemotherapy has become quite popular with oncologists and general practitioners. There are some basic scientific data addressing its mechanism of action, however, the vast amount of data is purely retrospective in nature. These studies vary in drug dosage and protocols used making assessment between studies challenging. On top of this, there are no good surrogate markers for efficacy to help guide clinicians. Last, the use of metronomic therapy has opened our eyes to the challenges...
American College of Veterinary Pharmacists

Disparities in Ovarian Cancer: Increasing Awareness to Improve Risk Assessment and Outcomes

Ovarian cancer is the most common cause of cancer death in women with gynecologic malignancy and the fifth leading cause of cancer death in the US. Although the incidence of ovarian cancer is higher among White women than Black women, studies have identified disparities in assessment, care and outcomes seen among Black women with ovarian cancer. It has been shown that outcomes in clinical oncology can be improved when care is delivered by high performance teams. This activity was designed by ...
American Academy of CME

How I Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)

In this point-counterpoint digital activity, two expert faculty discuss and debate treatment selection for patients with PNH through case-based scenarios. Faculty review mechanisms of action, clinical trial data, and real-world evidence supporting divergent treatment strategies for the presented cases. How do the experts make their initial treatment selections? Why might they choose a C5 inhibitor or a C3 inhibitor? How do they assess response to treatment, and what do they do when treatment r...
ACHL

Navigating New Evidence in the Treatment of HER2-Expressing Metastatic Breast Cancer in Rural and Underserved Communities

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview Over the past decades, the emergence of novel targeted therapies in combination with endocrine therapy has improved outcomes for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. However, oncology clinicians in rural and ...
Postgraduate Institute for Medicine and RME Collaborative.

Navigating the Evolving Treatment Landscape of Renal Cell Carcinoma to Ensure Equitable Access to Quality Care

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview Therapeutic options for metastatic renal cell carcinoma (RCC) have expanded over the last decade and now include targeted therapies as well as immunotherapies. However, workforce shortages, low rates of recruitment into clinical trials, racial and socioeconomic inequities, a...
Talem Health and RME Collaborative.

Integrating PARP Inhibitors Into Treatment for Advanced Ovarian Cancer: Strategies for Improving Care and Outcomes

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview In recent years, the emergence of novel therapeutic agents has led to improved outcomes for patients with advanced and/or platinum-resistant ovarian cancer. Yet, even with improved treatment options, oncology teams in rural and underserved settings are challenged to provide ...
Postgraduate Institute for Medicine and RME Collaborative.

Internal Medicine Comprehensive Review and Update 2024 - LIVE STREAMING

Comprehensive, Evidence-Based Updates for Internal Medicine and Its Subspecialties This program, the 64th annual Internal Medicine Update from the leading clinical faculty of Harvard Medical School and Massachusetts General Hospital, provides comprehensive, high-yield instruction to ensure clinicians are current with the latest evidence and best practices to optimize patient care. This program covers the breadth of Internal Medicine subspecialties, including: • Cardiovascular Medicine ...
Harvard Medical School

Intensive Review of Internal Medicine - IN PERSON or LIVE STREAMING

The Acclaimed Clinical Update and Board Review With more than 150 lectures, case discussions, and board preparation sessions, this CME program is one of the most comprehensive reviews of internal medicine offered by the clinical faculty of Harvard Medical School. It offers accelerated learning: - For clinicians seeking a practical and comprehensive review that ensures you are up to date across all major fields of internal medicine: • Newer options for diagnosis: what to choose, w...
Harvard Medical School

Hot Topics in Blood-based Cancer Screening: Key Information on Multi-Cancer Early Detection from 2023 Spring Oncology Meetings

Early detection of cancer is essential to reducing the significant burdens associated with it. When cancer is detected at earlier stages, treatments can be initiated sooner, resulting in improved outcomes, reduced morbidity and mortality, and better quality of life. While the implementation of current screening guidelines has resulted in an overall reduction in cancer deaths, only 25% of cancers are diagnosed using traditional screening modalities, leaving much room for improvement. Blood-base...
Integritas Communications

Dialogues about FOP: What Patients Wish More Doctors Knew to Enhance Early Recognition and Management

Target Audience The educational design of this activity addresses the needs of the primary audience of PCPs, pediatricians, dermatologists, endocrinologists, occupational therapists, oncologists, general practice NPs and PAs, specialist NPs and PAs, and the secondary audience of orthopedists, bone specialists, rheumatologists, pediatric rheumatologists, genetic counselors, and dentists. Statement of Need/Program Overview Fibrodysplasia ossificans progressiva (FOP) causes abnormal bone for...
Relias LLC

Clinical Updates in Chronic Graft-versus-Host Disease and Applications for Academic and Community Practice

Target Audience The target audience for this activity are hematologists, oncologists, immunologists, and bone-marrow transplant specialists. Program Overview Chronic graft-versus-host disease (cGvHD) is a common, multi-symptom complication of allogeneic transplantation that severely affects patient well-being. While the medical systems and resources differ between academic and community healthcare settings, clinicians practicing in both environments would benefit from education about rece...
Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC (PQHE)

Hitting The Bullseye in NSCLC

Lung cancer is the second most common cancer in both men and women and is the leading cause of cancer-related deaths. The majority of lung cancer cases are categorized as NSCLC, which has a low overall 5-year survival rate, especially when it is diagnosed at advanced, unresectable stages. Recent advances in the treatment landscape have yielded promising improvements in progression-free survival and overall survival; however, outcomes are dependent on numerous factors, including the evaluation ...
Integritas Communications

Cleveland Clinic 13th Annual Neurology Update

Cleveland Clinic’s 13th Annual Neurology Update features a faculty of more than a dozen thought leaders discussing the most current clinically focused information regarding diagnosis, medication and therapy for a wide variety of neurologic conditions. This comprehensive review will detail strategies, procedures and best practices throughout the specialty. Neurologists, general practitioners, nurses and physician assistants will all benefit from the latest information impacting the practice...
Meetings By Mail®

Cleveland Clinic 21st Intensive Review of Cardiology

Cleveland Clinic’s acclaimed faculty shares its unparalleled expertise with its 21st Intensive Review of Cardiology. This Board and re-certification resource serves as a forum to critically review current thinking and management of all major cardiovascular disciplines. Focus is placed on the delivery of contemporary medicine, including complex patient management and decision-making for practicing cardiologists. Worth up to 15.75 AMA PRA Category I Credits™, this enduring material is also...
Meetings By Mail®

Nursing Management of Tumor Lysis Syndrome

STATEMENT OF NEED Tumor lysis syndrome (TLS) is an oncological emergency that occurs when massive tumor lysis causes the rapid release of intracellular components into the bloodstream. Electrolyte imbalances characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia may be severe enough to cause acute renal failure, cardiac arrhythmias, seizures, and even death. Current advances in cancer therapies can increase the incidence of TLS; therefore, identification of patien...
i3 Health

Treatment Considerations in Cutaneous Melanoma: From Early Stage to Late/Advanced Stage

Jason J. Luke, MD, discusses the impact of evolving therapies on the disease burden, survival, and treatment tolerability for patients with cutaneous melanoma. Recent clinical trial results and guideline updates for both perioperative and metastatic cutaneous melanoma are reviewed. To provide patient-centric care, Dr. Luke shares his expert insights and recommendations for individualizing treatment selection and sequencing, as well as providing supportive care and adverse event management.
Annenberg Center for Health Sciences at Eisenhower

PARP Inhibition as Ovarian Cancer Maintenance Therapy: Improving Patient Outcomes as a Multidisciplinary Team

Ovarian cancer (OC) is often diagnosed at an advanced stage and has generally poor survival rates¬"even after aggressive surgical management and chemotherapy. Without maintenance therapy, approximately 70% of patients relapse within 3 years of treatment. Recent clinical trials of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors have demonstrated substantial efficacy as maintenance therapy for OC patients. Additionally, clinical evidence suggests that daily monitoring of pati...
University of Cincinnati

Expanding the Benefit of Quality Improvement Programs: Sustainable Solutions to Achieve Therapeutic Goals for Patients with Myelofibrosis

Achieve measurable changes to improve your patients’ outcomes with this simple, systematic approach for quality improvement for application at any practice setting. Complete an assessment to understand where your practice’s performance falls relative to identified goals, which guides development of personalized action items. Access the framework and tools you need to measure your understanding.
ACHL

Therapeutic Advancements for the Treatment of High-Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life

Stay up to date on the evolving risk classification for myelodysplastic syndromes (MDS) and current treatment guidelines for patients with high-risk disease in this self-directed education with leading oncology experts. Expert commentary from Courtney DiNardo, MD from MD Anderson Cancer Center and Dr. Dan Pollyea from the University of Colorado School of Medicine provides insights on emerging therapies that could soon improve management of high-risk MDS. Be ready to incorporate these emerging ...
ACHL

Sustainable Solutions to Achieve Therapeutic Goals for Patients with Myelofibrosis

When it comes to treating your patients with myelofibrosis (MF), are you applying the latest guidance in practice? Evidence shows that it takes an average of 17 years for evidence to change practice but how can we incorporate treatment advances to improve patient outcomes today? This activity looks to bridge the chasm between education and implementation by framing available evidence and guideline recommendations for MF, including diagnosis, risk stratification, JAK inhibition, monitoring resp...
ACHL

Update in Clinical Cardiology - LIVE STREAMING or IN PERSON

The Comprehensive Clinical Cardiology Update Evaluation • Treatment • Patient Care • Procedures • Challenging Cases Update in Clinical Cardiology will be held on October 16 " 18, 2024. You have the option to attend either online as the course is live streamed or in person in Boston, MA. OVERVIEW This course provides comprehensive updates for state-of-the-art care and guidance to incorporate them into daily practice to optimize patient outcomes. Coverage includes: • ...
Harvard Medical School

Multi-Modality Screening of the Breast

This activity is geared toward breast radiologists, general radiologists and trainees. Be ready to review key concepts in breast imaging, refresh yourself on recent updates and delve into innovations that are changing how we practice breast imaging today. Lectures are provided by a distinguished faculty who specialize in breast imaging, breast surgical oncology, or breast pathology. This diverse faculty group from various organizations have a wealth of clinical and teaching experience. Don’t...
AOCR

Best Practices in Multiple Myeloma Care: Opportunities to Improve Outcomes in Community Settings

As nurses and APPs are well positioned to educate, support, and coordinate care for patients with multiple myeloma, having insight into the evolving trajectory of the disease will enhance their ability to provide quality patient care and identify and eliminate barriers. Addressing barriers to care remains key in ensuring access to novel therapies and improving quality of life. Having an understanding of the advances and increasing complexity of care of the patient with multiple myeloma will pr...
American Academy of CME

Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies

The expanding armamentarium of therapies for R/R MM shifts therapy selection from an algorithmic approach to an individualized strategy that requires consideration of the nature of relapse, prior therapies, treatment-related toxicities, as well as patient comorbidities and preferences. With the introduction of novel bispecific antibodies, specialists must learn how to optimally sequence these therapies and manage adverse events. To help clinicians navigate this complexity, individualized educa...
ACHL

Nurses Light the Path: Empowering Patients to Improve Breast Cancer Screening and Clinical Trial Representation

Target Audience The primary target audience for this activity is Oncology Nursing Professionals (APRN, NP, RN). Program Overview For women with breast cancer and those at risk, disparities in screening and clinical-trial enrollment exist, particularly among racial and ethnic minority populations. Awareness of these disparities can ensure timely screening practices and help address patient fears and concerns regarding clinical trials that inhibit diverse representation in research. Younger...
Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with Black Nurses Rock.

The latest insights into rare blood disorders: Diagnosis and treatment strategies

Because immune-mediated rare blood disorders are uncommon, healthcare providers often lack the knowledge and experience necessary to identify, diagnose, and treat them in accordance with best practices. As a result, there are significant gaps in care, including delays in diagnosis and suboptimal treatment. To ensure that more patients with these rare disorders are offered quality, evidence-based care, it is essential that healthcare providers possess up-to-date information about best practices...
CMEology

Addressing Key Questions About BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma

ACTIVITY DESCRIPTION Though treatment advances have improved outcomes for most patients, MM remains an incurable disease characterized by continuous relapse. However, the treatment landscape for relapsed/refractory MM (RRMM) has expanded in recent years, and patients who relapse and/or become refractory to initial therapies are benefiting from the increasing availability of a diverse range of novel agents, including B-cell maturation antigen (BCMA)"targeted immunotherapies. These agents ...
Multiple Myeloma Research Foundation, RedMedEd, and Purdue University College of Pharmacy

Recent Advances in the Treatment and Management of Endometrial Cancer

This live activity is designed for oncologists, obstetrics & gynecologists, primary care physicians, nurses and pharmacists engaged in the care of patients with endometrial cancer. This activity will represent a thorough team approach to patient care. Further, this activity will address the following needs: Clinicians require a review of risk factors and symptoms of endometrial cancer, as well as appropriate management of patients. Clinicians need further education regarding new and...
American Academy of CME

Across the Compendium: Practical Pathways to Integrate Bispecific Antibodies Into Care for Patients With Relapsed/Refractory Multiple Myeloma

As the armamentarium of therapies for relapsed/refractory multiple myeloma (R/R MM) expands, several factors, including previous therapy, treatment-related toxicity, and comorbidities must be considered as part of clinical decision making. To assist the multidisciplinary treatment team in these efforts, and ensure patients are receiving cutting-edge cancer care, this immersive digital practice guide highlights best practices, clinical pearls, and strategies to overcome pitfalls in the administ...
ACHL

Exploring New Treatment Advances for Acid Sphingomyelinase Deficiency in Adults

STATEMENT OF NEED Acid sphingomyelinase deficiency (ASMD) is a rare, hereditary lysosomal storage disease with multisystemic manifestations, including splenomegaly, hepatomegaly, interstitial lung disease, dyslipidemia, bone marrow and lymph node involvement, and sometimes neurological and peripheral nerve involvement. While the most severe form of ASMD, infantile neurovisceral ASMD, results in death in early childhood, chronic forms of ASMD have more prolonged survival but are associated w...
i3 Health

Nuclear Medicine and Molecular Imaging Update

The Mid East Chapter of the Society of Nuclear Medicine and Molecular Imaging’s historic 50th Annual Conference presents nuclear medicine’s latest trends, advances and procedures. Adapted for the enduring material audience, Nuclear Medicine and Molecular Imaging Update features a dozen faculty members presenting this specialty’s impact on imaging, cardiology, neurology, endocrinology, oncology, rheumatology, pediatrics and much more. Practice enhancements and professional development w...
Meetings By Mail®

Biosimilars in Osteoporosis: Highlights from the ASBMR

Biosimilars are large, complex molecules made from living organisms that are highly similar to their reference biologic and are administered in the same way, with the same strength and dosage, and clinically meaningful differences in safety, purity, and potency. Incorporating biosimilars into the management of osteoporosis, known as a silent chronic disease responsible for 13 million fragility fractures worldwide, provide a more affordable version of osteoporosis medication, and an alternat...
EXCEL Continuing Education

Cancer Treatment Related Cognitive Impairment - Connie Carson, PhD, CCC-SLP

Oncology professionals, nurses, neuropsychologists, and psychologists have established cancer treatment related cognitive impairment (CTRCI) as a common side-effect of cancer treatment, impacting as many as 75% of cancer survivors; yet, speech-language pathologists have been silent in establishing their role in the treatment of this phenomenon. This presentation will provide the necessary background for them to be able to do so. Clinical symptoms will be defined and therapeutic suggestions off...
Speech Therapy Professional Development

Cultural Awareness in Clinical Practice

Cultural Awareness in Clinical Practice is a 3-hour online continuing education (CE) course that provides the foundation for achieving cultural competence and diversity in healthcare settings. Cultural competence, responding to diversity and inclusion, are important practices for healthcare professionals. This course will help you to gain an awareness of bias and provide strategies to adjust your clinical mindset and therapeutic approach to adapt to “the other” " people who differ ...
Professional Development Resources

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map